<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Histomorphological evaluation of bone marrow trephines and smears represents the major approach to diagnose the <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_512'>myeloproliferative diseases</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e>) and the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, rising insights into molecular pathogenesis of human diseases strengthen the attempt of pathologists to define and to detect underlying defects beyond the microscope </plain></SENT>
<SENT sid="2" pm="."><plain>Since discovery of the Philadelphia chromosome in <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> as the first specific molecular abnormality ever detected in a human <z:hpo ids='HP_0002664'>neoplasia</z:hpo> the gain of knowledge of molecular pathomechanisms in Philadelphia chromosome negative (Ph-) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> was rather sparse </plain></SENT>
<SENT sid="3" pm="."><plain>A decisive breakthrough in Ph <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> was the finding of JAK2 (V617F) derived from a somatic point mutation in the majority of patients with <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="C0032463" disease_type="Neoplastic Process" abbrv="PV">P.vera</z:e>) and half of patients with <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> (ET) and primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (PMF) </plain></SENT>
<SENT sid="4" pm="."><plain>It therefore can not be overestimated that detection of JAK2 (V617F) in a suspective myeloproliferation now enables a clearcut discrimination of a true Ph <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> from a reactive state, e.g. <z:e sem="disease" ids="C0032463" disease_type="Neoplastic Process" abbrv="PV">P.vera</z:e> from reactive <z:hpo ids='HP_0001901'>erythrocytosis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, a basic principle of molecular defects demonstrable in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> and related disorders seems to be the involvement of genes with kinase activities </plain></SENT>
<SENT sid="6" pm="."><plain>Some of those genes will be discussed in more detail </plain></SENT>
<SENT sid="7" pm="."><plain>In primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, karyotyping via classical cytogenetics is the predominant molecular approach to estimate prognosis, e.g. -Y, del(5q) and del(20q) represent favourable anomalies </plain></SENT>
<SENT sid="8" pm="."><plain>Indeed, in <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q- syndromes</z:e> karyotyping enables definite subtyping and allows clinicians and patients to expect a good prognosis </plain></SENT>
<SENT sid="9" pm="."><plain>Until now, dozens of molecular abnormalities such as mutations in AML1, FLT3 and Ras as well as epigenetic alterations of genes have been identified to various degrees in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes </plain></SENT>
<SENT sid="10" pm="."><plain>Some of them seem to be involved in disease initiation ("master event") and others might indicate disease progression </plain></SENT>
<SENT sid="11" pm="."><plain>However, even though useful for further dissection of molecular pathomechanisms the majority of aberrations currently does not serve as potent markers in the daily routine </plain></SENT>
<SENT sid="12" pm="."><plain>Nevertheless, in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> the importance of molecular analyses for diagnosis, estimation of prognosis, and disease monitoring will further increase in a foreseeable period of time </plain></SENT>
</text></document>